3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 3
3
Phase 1
2
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, T-Cell, Peripheral
3
Recurrence
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Smoking
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia-Lymphoma, Adult T-Cell
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
17
Etoposide
10
fludarabine
9
Whole-Body Irradiation
9
Brentuximab Vedotin
9
Melphalan
8
fludarabine phosphate
7
Vincristine
7
Mycophenolic Acid
7
Gemcitabine
7
Doxorubicin
7
Prednisone
6
Granulocyte Colony-Stimulating Factor
6
Busulfan
6
Vorinostat
5
Rituximab
5
Peripheral Blood Stem Cell Transplantation
5
Lenalidomide
5
Filgrastim
5
Cytarabine
5
Bortezomib
5
romidepsin
4
pembrolizumab
4
duvelisib
4
Tacrolimus
4
Stem Cell Transplantation
4
Carmustine
4
etoposide phosphate
3
Sirolimus
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT00364923
2019-12-19
PROPEL
Acrotech Biopharma Inc.
Phase 2
Completed
115 enrolled
11 charts